Candel Therapeutics Management
Management criteria checks 3/4
Candel Therapeutics' CEO is Paul-Peter Tak, appointed in Sep 2020, has a tenure of 3.58 years. total yearly compensation is $1.84M, comprised of 36.3% salary and 63.7% bonuses, including company stock and options. directly owns 0.33% of the company’s shares, worth $529.04K. The average tenure of the management team and the board of directors is 2.2 years and 5.4 years respectively.
Key information
Paul-Peter Tak
Chief executive officer
US$1.8m
Total compensation
| CEO salary percentage | 36.3% |
| CEO tenure | 3.6yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.2yrs |
| Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Apr 15Candel gets European orphan drug designation for brain, spinal cord tumor treatment
Sep 15Candel Therapeutics appoints CFO, chief medical officer
Sep 07Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies
Oct 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$38m |
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$32m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$2m | US$670k | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$12m |
| Jun 30 2022 | n/a | n/a | -US$20m |
| Mar 31 2022 | n/a | n/a | -US$33m |
| Dec 31 2021 | US$957k | US$545k | -US$36m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$35m |
| Mar 31 2021 | n/a | n/a | -US$20m |
| Dec 31 2020 | US$3m | US$135k | -US$18m |
Compensation vs Market: Paul-Peter's total compensation ($USD1.84M) is about average for companies of similar size in the US market ($USD1.60M).
Compensation vs Earnings: Paul-Peter's compensation has increased whilst the company is unprofitable.
CEO
Paul-Peter Tak (62 yo)
3.6yrs
Tenure
US$1,844,971
Compensation
Dr. Paul-Peter Tak, M.D. PH.D. FMEDSCI, has been Member of Advisory Board at SecondWave Systems, Inc. from March 2024. He serves as President & Chief Executive Officer at Candel Therapeutics, Inc. since Se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.6yrs | US$1.84m | 0.33% $ 529.0k | |
| Founder & Director | 22.3yrs | US$49.32k | 10.75% $ 17.5m | |
| Chief Technical & Development Officer | 2yrs | US$916.02k | 0.11% $ 182.1k | |
| Chief Scientific Officer | 2.2yrs | US$908.30k | 0.097% $ 157.5k | |
| Interim CFO | 1.1yrs | no data | 0.27% $ 439.3k | |
| Chief People Officer | no data | no data | no data | |
| Chief Regulatory Officer | 3.5yrs | no data | 0% $ 0 | |
| Chief Medical Officer | 1.6yrs | no data | 0.46% $ 748.6k |
2.2yrs
Average Tenure
56yo
Average Age
Experienced Management: CADL's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.6yrs | US$1.84m | 0.33% $ 529.0k | |
| Founder & Director | 22.3yrs | US$49.32k | 10.75% $ 17.5m | |
| Independent Director | 1.7yrs | US$50.98k | 0.13% $ 210.7k | |
| Member of Research Advisory Board & Director | 6.6yrs | US$57.24k | 0% $ 0 | |
| Independent Chairman | 5.4yrs | US$106.24k | 7.92% $ 12.9m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.4yrs | US$71.24k | 1.48% $ 2.4m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.4yrs
Average Tenure
65.5yo
Average Age
Experienced Board: CADL's board of directors are considered experienced (5.4 years average tenure).